Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel

Douglas A. Jabs, James (Jim) Rosenbaum, C. Stephen Foster, Gary N. Holland, Glenn J. Jaffe, James S. Louie, Robert B. Nussenblatt, E. Richard Stiehm, Howard Tessler, Russell N. Van Gelder, Scott M. Whitcup, David Yocum

Research output: Contribution to journalArticle

599 Citations (Scopus)

Abstract

PURPOSE: To provide recommendations for the use of immunosuppressive drugs in the treatment of patients with ocular inflammatory disorders. PARTICIPANTS: A 12-person panel of physicians with expertise in ophthalmologic, pediatric, and rheumatologic disease, in research, and in the use of immunosuppressive drugs in patient care. EVIDENCE: Published clinical study results. Recommendations were rated according to the quality and strength of available evidence. PROCESS: The panel was convened in September of 1999 and met regularly through May 2000. Subgroups of the panel summarized and presented available information on specific topics to the full panel; recommendations and ratings were determined by group consensus. CONCLUSIONS: Although corticosteroids represent one of the mainstays in the management of patients with ocular inflammation, in many patients, the severity of the disease, the presence of corticosteroid side effects, or the requirement for doses of systemic corticosteroids highly likely to result in corticosteroid complications supports the rationale for immunosuppressive drugs (for example, antimetabolites, T-cell inhibitors, and alkylating agents) being used in the management of these patients. Because of the potential for side effects, treatment must be individualized and regular monitoring performed. With careful use of immunosuppressive drugs for treatment of ocular inflammatory disorders, many patients will benefit from them either with better control of the ocular inflammation or with a decrease in corticosteroid side effects. (C) 2000 by Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)492-513
Number of pages22
JournalAmerican Journal of Ophthalmology
Volume130
Issue number4
DOIs
StatePublished - Oct 2000

Fingerprint

Immunosuppressive Agents
Adrenal Cortex Hormones
Guidelines
Pharmaceutical Preparations
Inflammation
Antimetabolites
compound A 12
Alkylating Agents
Patient Care
Therapeutics
Pediatrics
Physicians
T-Lymphocytes
Research

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders : Recommendations of an expert panel. / Jabs, Douglas A.; Rosenbaum, James (Jim); Foster, C. Stephen; Holland, Gary N.; Jaffe, Glenn J.; Louie, James S.; Nussenblatt, Robert B.; Stiehm, E. Richard; Tessler, Howard; Van Gelder, Russell N.; Whitcup, Scott M.; Yocum, David.

In: American Journal of Ophthalmology, Vol. 130, No. 4, 10.2000, p. 492-513.

Research output: Contribution to journalArticle

Jabs, DA, Rosenbaum, JJ, Foster, CS, Holland, GN, Jaffe, GJ, Louie, JS, Nussenblatt, RB, Stiehm, ER, Tessler, H, Van Gelder, RN, Whitcup, SM & Yocum, D 2000, 'Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel', American Journal of Ophthalmology, vol. 130, no. 4, pp. 492-513. https://doi.org/10.1016/S0002-9394(00)00659-0
Jabs, Douglas A. ; Rosenbaum, James (Jim) ; Foster, C. Stephen ; Holland, Gary N. ; Jaffe, Glenn J. ; Louie, James S. ; Nussenblatt, Robert B. ; Stiehm, E. Richard ; Tessler, Howard ; Van Gelder, Russell N. ; Whitcup, Scott M. ; Yocum, David. / Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders : Recommendations of an expert panel. In: American Journal of Ophthalmology. 2000 ; Vol. 130, No. 4. pp. 492-513.
@article{690368673ecb4d6b817f359efa437db8,
title = "Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel",
abstract = "PURPOSE: To provide recommendations for the use of immunosuppressive drugs in the treatment of patients with ocular inflammatory disorders. PARTICIPANTS: A 12-person panel of physicians with expertise in ophthalmologic, pediatric, and rheumatologic disease, in research, and in the use of immunosuppressive drugs in patient care. EVIDENCE: Published clinical study results. Recommendations were rated according to the quality and strength of available evidence. PROCESS: The panel was convened in September of 1999 and met regularly through May 2000. Subgroups of the panel summarized and presented available information on specific topics to the full panel; recommendations and ratings were determined by group consensus. CONCLUSIONS: Although corticosteroids represent one of the mainstays in the management of patients with ocular inflammation, in many patients, the severity of the disease, the presence of corticosteroid side effects, or the requirement for doses of systemic corticosteroids highly likely to result in corticosteroid complications supports the rationale for immunosuppressive drugs (for example, antimetabolites, T-cell inhibitors, and alkylating agents) being used in the management of these patients. Because of the potential for side effects, treatment must be individualized and regular monitoring performed. With careful use of immunosuppressive drugs for treatment of ocular inflammatory disorders, many patients will benefit from them either with better control of the ocular inflammation or with a decrease in corticosteroid side effects. (C) 2000 by Elsevier Science Inc.",
author = "Jabs, {Douglas A.} and Rosenbaum, {James (Jim)} and Foster, {C. Stephen} and Holland, {Gary N.} and Jaffe, {Glenn J.} and Louie, {James S.} and Nussenblatt, {Robert B.} and Stiehm, {E. Richard} and Howard Tessler and {Van Gelder}, {Russell N.} and Whitcup, {Scott M.} and David Yocum",
year = "2000",
month = "10",
doi = "10.1016/S0002-9394(00)00659-0",
language = "English (US)",
volume = "130",
pages = "492--513",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders

T2 - Recommendations of an expert panel

AU - Jabs, Douglas A.

AU - Rosenbaum, James (Jim)

AU - Foster, C. Stephen

AU - Holland, Gary N.

AU - Jaffe, Glenn J.

AU - Louie, James S.

AU - Nussenblatt, Robert B.

AU - Stiehm, E. Richard

AU - Tessler, Howard

AU - Van Gelder, Russell N.

AU - Whitcup, Scott M.

AU - Yocum, David

PY - 2000/10

Y1 - 2000/10

N2 - PURPOSE: To provide recommendations for the use of immunosuppressive drugs in the treatment of patients with ocular inflammatory disorders. PARTICIPANTS: A 12-person panel of physicians with expertise in ophthalmologic, pediatric, and rheumatologic disease, in research, and in the use of immunosuppressive drugs in patient care. EVIDENCE: Published clinical study results. Recommendations were rated according to the quality and strength of available evidence. PROCESS: The panel was convened in September of 1999 and met regularly through May 2000. Subgroups of the panel summarized and presented available information on specific topics to the full panel; recommendations and ratings were determined by group consensus. CONCLUSIONS: Although corticosteroids represent one of the mainstays in the management of patients with ocular inflammation, in many patients, the severity of the disease, the presence of corticosteroid side effects, or the requirement for doses of systemic corticosteroids highly likely to result in corticosteroid complications supports the rationale for immunosuppressive drugs (for example, antimetabolites, T-cell inhibitors, and alkylating agents) being used in the management of these patients. Because of the potential for side effects, treatment must be individualized and regular monitoring performed. With careful use of immunosuppressive drugs for treatment of ocular inflammatory disorders, many patients will benefit from them either with better control of the ocular inflammation or with a decrease in corticosteroid side effects. (C) 2000 by Elsevier Science Inc.

AB - PURPOSE: To provide recommendations for the use of immunosuppressive drugs in the treatment of patients with ocular inflammatory disorders. PARTICIPANTS: A 12-person panel of physicians with expertise in ophthalmologic, pediatric, and rheumatologic disease, in research, and in the use of immunosuppressive drugs in patient care. EVIDENCE: Published clinical study results. Recommendations were rated according to the quality and strength of available evidence. PROCESS: The panel was convened in September of 1999 and met regularly through May 2000. Subgroups of the panel summarized and presented available information on specific topics to the full panel; recommendations and ratings were determined by group consensus. CONCLUSIONS: Although corticosteroids represent one of the mainstays in the management of patients with ocular inflammation, in many patients, the severity of the disease, the presence of corticosteroid side effects, or the requirement for doses of systemic corticosteroids highly likely to result in corticosteroid complications supports the rationale for immunosuppressive drugs (for example, antimetabolites, T-cell inhibitors, and alkylating agents) being used in the management of these patients. Because of the potential for side effects, treatment must be individualized and regular monitoring performed. With careful use of immunosuppressive drugs for treatment of ocular inflammatory disorders, many patients will benefit from them either with better control of the ocular inflammation or with a decrease in corticosteroid side effects. (C) 2000 by Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033807387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033807387&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(00)00659-0

DO - 10.1016/S0002-9394(00)00659-0

M3 - Article

C2 - 11024423

AN - SCOPUS:0033807387

VL - 130

SP - 492

EP - 513

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -